Literature DB >> 16466011

[Inflammatory markers and adiponectin plasma level in patients with type 2 diabetes].

Monika Zurawska-Kliś1, Józef Drzewoski.   

Abstract

INTRODUCTION: In patients with carbohydrate or lipid disturbances higher inflammatory markers levels and lower adiponectin levels were observed. These observations suggest the potential role of those markers in the pathogenesis of diabetes, obesity and atherosclerosis. INVESTIGATED GROUP AND METHODS: 25 type 2 diabetic patients (group A) and 15 patients without diabetes (group B) were included into the study. Glycated haemoglobin (HbAlc), total cholesterol and triglycerides, interleukin 6 (IL-6), tumor necrosis factor alpha (TNFalpha) and adiponectin levels were measured in blood samples. Fasting plasma glucose and fasting plasma insulin were measured to calculate index of insulin resistance (homeostasis model assessment--IR/HOMA-IR/).
RESULTS: Mean adiponectin level was significantly lower in patients with type 2 diabetes than in control patients (7,4 microg/ml vs 12,3 microg/ml; p<0,05). Blood levels of fasting insulin, IL-6, TNFalpha and HOMA-IR index were higher in people with diabetes than in control subjects but the differences were not statistically significant. No significant correlations were observed between adiponectin and inflammatory markers level and total cholesterol, triglyceride, HOMA-IR level and blood pressure.
CONCLUSIONS: The findings indicate that adiponectin level is lower in patients with type 2 diabetes. We did not manage to confirm significantly elevated inflammatory markers levels in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16466011

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  1 in total

1.  Relationship of serum adiponectin with blood lipids, HbA(1)c, and hs-CRP in type II diabetic postmenopausal women.

Authors:  Mohammad Taghi Goodarzi; Hossein Babaahmadi-Rezaei; Manizheh Kadkhodaei-Eliaderani; Shahram Haddadinezhad
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.